RxDoctor Payments Data

Ook Kim, MD

Internal Medicine · Riverside, CANPI 1285849992

Payments from drug & device makers

$190in general payments, 2019–2025

Across 10 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$51
  • AbbVie$50
  • Johnson & Johnson$24
  • Optinose US, Inc.$22
  • AstraZeneca$16
  • Merck$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$51
AbbVie(2 entities)3$50
Johnson & Johnson1$24
Optinose US, Inc.1$22
AstraZeneca1$16
Merck1$15
Lilly USA, LLC1$12

How this compares

$190 in reported general payments places this provider in the 50th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,877
Medicare patients
166
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$75,323
OzempicSemaglutide53$63,871
FarxigaDapagliflozin Propanediol36$37,101
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$29,622
MounjaroTirzepatide30$28,864
JanuviaSitagliptin Phosphate21$28,093
JardianceEmpagliflozin16$25,701
SavellaMilnacipran Hcl37$18,401
XareltoRivaroxaban13$17,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,956
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen318$8,979
Wixela InhubFluticasone Propion/Salmeterol20$8,133
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$7,035
Rosuvastatin Calcium333$5,638
Losartan Potassium334$5,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$51$41,57857 claims
AstraZenecaFarxiga$16$37,10136 claims
Lilly USA, LLCMounjaro$12$28,86430 claims
MerckJanuvia$15$28,09321 claims
AbbVieSavella$50$18,40137 claims
Johnson & JohnsonXarelto$24$17,18413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →